Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

X4 Pharmaceuticals, Inc.

arsanis.com
Filed: Jun 30, 2026BOSTON, MACIK: 0001501697Biotechnology
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

X4 Pharmaceuticals appointed Kelly Gold as a Class II director effective July 1, 2026, expanding the board from five to six members. Gold brings significant finance and corporate development experience from her CFO role at CAMP4 Therapeutics, strengthening the company's governance and audit oversight.

Key Takeaways

Board expansion from 5 to 6 directors signals growth and enhanced governance capacity

Kelly Gold's CFO background at CAMP4 Therapeutics brings finance and corporate development expertise directly to X4's audit committee

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJun 30, 2026
Item5.02
CategoryExecutive Change
CIK0001501697
Accession #xfor-20260630
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
board change

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings